# Bioqube Ventures

> Bioqube Ventures is a VC fund backing Biotechnology and Therapeutics. See 18 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Hasselt, Belgium
- Total investments: 18
- Last investment: Jan 2026
- Lead investor: 33%
- Last fund: Jun 2020
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/bioqube-ventures
- X (Twitter): https://twitter.com/bioqubeventures
- Website: https://www.bioqubeventures.com/

Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope.

## Contacts

5 contacts available for Bioqube Ventures. Shizune tracks 5 team members at Bioqube Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bioqube-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $5.7M–$24M |
| Series A | $4M–$76M |
| Series B | $23M–$108M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 56% |
| Therapeutics | 8 | 44% |
| Life Science | 5 | 28% |
| Health Care | 4 | 22% |
| Medical | 3 | 17% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 22% |
| Series A | 4 | 22% |
| Series B | 3 | 17% |
| Series C | 1 | 6% |
| Series D | 1 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 17% |
| France | 2 | 11% |
| Norway | 1 | 6% |
| Belgium | 1 | 6% |
| Denmark | 1 | 6% |

8 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Debbie Dumont | Co-founder and Managing Partner | 4 | https://shizune.co/investors/profile/debbie-dumont |
| Debora Dumont | Co-Founder & Managing Partner | 4 | https://shizune.co/investors/profile/debora-dumont |
| Dirk Reyn | Managing Partner | 0 | https://shizune.co/investors/profile/dirk-reyn |
| Nico Vandervelpen | Co-founder and Managing Partner | 1 | https://shizune.co/investors/profile/nico-vandervelpen |
| Tom Heyman | Executive Partner | 0 | https://shizune.co/investors/profile/tom-heyman |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Primmune Therapeutics | Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability. | $23.3M | Series B | Jan 26, 2026 |  |
| Actithera | Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows. | $75.5M | Series A | Jul 09, 2025 |  |
| Spica Therapeutics | Spica Therapeutics is a biotech company to transform macrophage biology into breakthrough therapies for patients. | $11.4M | Seed | Jun 04, 2025 |  |
| Commit Biologics | Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer. The company was founded in 2021 and is headquartered in Aarhus, Denmark. | $5.7M | Seed | Jan 28, 2025 |  |
| Commit Biologics | Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer. The company was founded in 2021 and is headquartered in Aarhus, Denmark. | $5.7M | Seed | Jan 28, 2025 |  |
| SynOx Therapeutics | SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland. | $92M | Series B | Oct 30, 2024 |  |
| CatalYm | Catalym develops antibodies against a placental factor which is overexpressed by various tumour types. | $150M | Series D | Jul 16, 2024 |  |
| Commit Biologics | Commit Biologics is a biotechnology research company developing a novel immunotherapy platform for the treatment of cancer. The company was founded in 2021 and is headquartered in Aarhus, Denmark. | $17.3M | Seed | May 09, 2024 |  |
| SynOx Therapeutics | SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland. | $75M | Series B | Apr 22, 2024 |  |
| Bicara Therapeutics | Bicara Therapeutics, a wholly-owned subsidiary of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates the development of cutting-edge therapies for cancer. Synergies between thescientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation. | $165M | Series C | Dec 12, 2023 |  |

10 of 18 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 5 deals together
- [M Ventures](https://shizune.co/investors/profile/merckventures) — VC Fund, 4 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 3 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 3 deals together
- [Omega Funds](https://shizune.co/investors/profile/omega-funds) — VC Fund, 3 deals together
- [Eight Roads Ventures](https://shizune.co/investors/profile/eight-roads-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Life Science Investors in Denmark](https://shizune.co/investors/life-science-investors-denmark)
- [Medical VC Funds in Denmark](https://shizune.co/investors/medical-vc-funds-denmark)
- [Life Science VC Funds in Denmark](https://shizune.co/investors/life-science-vc-funds-denmark)
- [Biotechnology VC Funds in Denmark](https://shizune.co/investors/biotechnology-vc-funds-denmark)
- [Health Care VC Funds in Denmark](https://shizune.co/investors/health-care-vc-funds-denmark)
- [Biotech VC Funds in Denmark](https://shizune.co/investors/biotech-vc-funds-denmark)

## FAQ

### What does Bioqube Ventures invest in?

Bioqube Ventures invests primarily in Biotechnology, Therapeutics and Life Science startups, most often at Seed and Series A stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Bioqube Ventures's check size?

Bioqube Ventures typically joins rounds of $5.7M–$24M at Seed, $4M–$76M at Series A and $23M–$108M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bioqube Ventures participates in.

### How do I contact Bioqube Ventures?

Public channels for Bioqube Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Bioqube Ventures?

The team at Bioqube Ventures includes Debbie Dumont (Co-founder and Managing Partner), Debora Dumont (Co-Founder & Managing Partner) and Dirk Reyn (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co